Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"June 18, 2026 2 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . “
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses lingering questions on the potential risks that gender-affirming hormone therapy may have for transgender patients with inflammatory bowel disease. \u201cThere are a lot of unanswered questions in this field,\u201d Loftus, the Maxine and Jack Zarrow Family Professor of Gastroenterology at Mayo Clinic and chief medical editor of Healio Gastroenterology, said. \u201cWe have some data that gender-affirming hormone therapy doesn\u2019t appear to increase the risk of IBD flares in transgender individuals.\u201d In their 2023 retrospective multicenter study published in Clinical Gastroenterology and Hepatology, researchers Victor Chedid, MD, MS, and Kira Newman, MD, PhD, found no overall increase in IBD flares in the first year after patients started hormone therapy. However, their findings did highlight one crucial caveat: Patients with IBD who began hormone therapy with active disease or ongoing inflammation were more likely to experience a flare in the year that followed. Clinicians should also consider the risk for venous thromboembolism in patients with IBD receiving hormone therapy. Oral estradiol is known to increase VTE risk, which may be particularly relevant for patients with IBD, who are already at two- to threefold greater risk for VTE than the general population. One \u201cunanswered question\u201d is how overlapping risk factors interact, particularly when hospitalization adds another layer of thrombosis risk to the mix. \u201cThere is the question remaining about thromboembolism risk that needs to be further addressed,\u201d Loftus said. \u201cThere might be a role for temporarily stopping such therapy in patients with severe inflammation or hospitalization.\u201d In this month\u2019s issue of Healio Gastroenterology, Chedid, Newman and other experts from Rainbows in Gastro explore the evolving challenges facing transgender patients with IBD as access to gender-affirming hormone therapy comes under increasing political scrutiny. The discussion also highlights critical knowledge gaps about the psychosocial barriers transgender patients encounter in gastrointestinal care and the influence of stigma on patient outcomes. \u201cThe story also brings up the importance of having a welcoming, non-threatening environment for patients,\u201d Loftus said. \u201cMany patients who are transgender have had unpleasant experiences in the health care system so anything that we can do that says, \u2018we welcome all people\u2019 is a good thing.\u201d Published by: Sources\/Disclosures Source: Healio Interviews References:
Disclosures:
Loftus reports consulting for AbbVie, Alvotech, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Eli Lilly & Co., Fresenius Kabi, Gilead Sciences, Janssen and Takeda, and receiving research support from AbbVie, Bristol Myers Squibb, Celgene\/Receptos, Gilead, Janssen and Takeda. Ask a clinical question and tap into Healio AI’s knowledge base.
PubMed, enrolling\/recruiting trials, guidelines
Clinical Guidance, Healio CME, FDA news
Healio’s exclusive daily news coverage of clinical data
Learn more
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . “
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Source link<\/p>\n","protected":false},"author":1,"featured_media":2852,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2851","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/2851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2851"}],"version-history":[{"count":0,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/2851\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/media\/2852"}],"wp:attachment":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Healio](\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/hgld\/healio_gastro.svg?la=en&h=40&w=152&hash=2C654A538F2E250F5183D42A89FE0EC0\")
\n <\/div>\n<\/p><\/div>\n<\/p><\/div>\n